The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 1.82 million shares traded hands or 18.95% up from the average. Concordia International Corp (NASDAQ:CXRX) has declined 82.52% since March 1, 2016 and is downtrending. It has underperformed by 91.76% the S&P500.
The move comes after 8 months negative chart setup for the $263.76M company. It was reported on Oct, 4 by Barchart.com. We have $4.02 PT which if reached, will make NASDAQ:CXRX worth $36.93M less.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $76.08M for 0.87 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. GMP Securities downgraded the shares of CXRX in a report on Monday, August 15 to “Hold” rating. IBC initiated the shares of CXRX in a report on Monday, November 30 with “Sector Perform” rating. The company was reinitiated on Thursday, October 1 by RBC Capital Markets. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Hold” rating by TD Securities on Thursday, August 4. The stock has “Sector Outperform” rating given by Scotia Capital on Friday, October 16. The firm has “Neutral” rating by Goldman Sachs given on Monday, June 6. The stock has “Buy” rating given by Laurentian on Tuesday, March 29. The firm earned “Neutral” rating on Monday, August 15 by Goldman Sachs. The company was maintained on Tuesday, August 11 by Canaccord Genuity. The firm has “Sector Outperform” rating by Scotia Capital given on Tuesday, September 29.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: Finance.Yahoo.com which released: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” on September 29, 2016, also Business.Financialpost.com with their article: “Concordia International Corp takeover unlikely â€“ Goldman” published on September 27, 2016, Prnewswire.com published: “Shareholder Class Action Filed Against Concordia International Corp. – CXRX” on August 17, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: Businesswire.com and their article: “Robbins Arroyo LLP: Concordia International Corp. (CXRX) Misled Shareholders …” published on September 06, 2016 as well as Business.Financialpost.com‘s news article titled: “Concordia International Corp stock crashes on proposed U.K. legislation over …” with publication date: September 16, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.